Author:
Fröhner Michael,Wirth Manfred
Publisher
Springer Berlin Heidelberg
Reference68 articles.
1. Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM (2019) Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU Int 123:42–50
2. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132
3. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G (2008) Is there an optimal comorbidity index for prostate cancer? Cancer 112(5):1043–1050. https://doi.org/10.1002/cncr.23269
4. American Society of Anesthesiologists: ASA physical status classification system. http://www.asahq.org/clinical/physicalstatus.htm. Zugegriffen am 16.12.2020
5. American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO): clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. update (Update 2017). https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-guideline. Zugegriffen am 09.09.2020